ArticleMolecular biology reports2025
Inhibition of CD133 resulted in cell death, inhibition of angiogenesis, and limited migration in the melanoma cancer cell line.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ciprofloxacin beyond antibacterial therapy: pharmacological mechanisms, anticancer activity, and translational limitations.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelanoma, a form of skin cancer, develops as a result of melanocytes growing malignantly. The global incidence of melanoma is on the rise, posing significant public health challenges. Consequently, it holds the highest fatality rate among skin cancers and accounts for the majority of deaths. Accurately classifying the stages of this cancer is a crucial yet arduous task, particularly during patient diagnosis. Cancer stem cells, which are a type of tumor-initiating cell, have been extensively researched for their rapid proliferation, migration, and contribution to cancer recurrence. These cells, characterized by specific markers such as CD133, possess a significantly heightened ability to initiate cancer, making them crucial in developing therapeutic strategies. The current study intended to determine the CD133 siRNA impact on angiogenesis, apoptosis, migration, proliferation, and stemness characteristics in melanoma cancer in the SK-MEL3 cell line. METHODS AND
resultsFor this purpose, the wound healing test was used to evaluate the cells' migratory potential, and the results indicated a decrease in the migration rate. Colony formation assays were also done to measure the stemness properties, which showed decreased stemness features in SK-MEL3 cells. Furthermore, the qRT-PCR and western blot assays demonstrated that the CD133 silencing reduced its expression and gene expression in migration and stemness. Finally, co-culturing HUVEC cells with SK-MEL3 cells, which suppressed CD133 expression, decreased the expression of angiogenic genes.
conclusionThis study highlights the therapeutic potential of CD133-siRNA in tumor treatment, warranting further investigation in future animal and clinical trials.
Indexed as
Identifiers
40586969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.